News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Oncotelic Reports that It`s Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma

Al's Comment:

 Impressive results in the article but the underlying poster (http://oncotelic.com/wp-content/uploads/AACR-JCA-Glioma-Finalv3.pdf) is a little on the confusing side.  They talk about "chemo naive recurrent glioma" but I would assume most patients would get Temodar as newly diagnosed. Where do they find those patients who did not use Temodar? There might be something special about them.  Then they go on to show survivals with and without previous Temodar and with and without subsequent Temodar.  The best group appears to be the control group and the conclusion is that this treatment is not inferior to Temodar.  This might just be that the amount of text on a poster is limited and we have to wait for the published results to completely dissect the trial.


Posted on: 02/13/2019

Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740